Browse the evidence

Under volume-matched conditions, increasing resistance exercise training frequency from once per week to five times per week does not increase daily myofibrillar protein synthesis rates in young men.

If you are trying to build muscle, you do not need to train each muscle group every day. As long as you are doing the same total amount of work (volume) and lifting with sufficient intensity, training a muscle once a week will build muscle just as effectively as training it five times a week. Focus on getting your total reps and sets in, rather than worrying about frequency.

Vertical sleeve gastrectomy (VSG) induces durable metabolic benefits and weight loss in nonhuman primates that are independent of caloric intake, mediated by early increases in bile acids and short-chain fatty acids, reduced visceral adipose tissue inflammation, and a polarization of immune cells toward regulatory phenotypes.

Vertical sleeve gastrectomy (VSG) is a highly effective intervention for obesity that works through complex biological mechanisms beyond simple stomach size reduction. It triggers early increases in beneficial metabolites (bile acids, short-chain fatty acids) and shifts the immune system in fat tissue to reduce inflammation and improve insulin sensitivity. These changes occur even if caloric intake remains the same, indicating that VSG fundamentally alters how the body regulates energy and metabolism. For patients, this means VSG offers durable metabolic benefits, including improved glucose control and reduced visceral fat inflammation, which are critical for long-term health independent of weight loss alone.

Increasing resistance training volume from moderate (3 sets/exercise) to high (5 sets/exercise) does not improve lean mass or muscle thickness preservation during a moderate caloric deficit in trained males.

If you are dieting to lose fat but want to keep your muscle, you do not need to drastically increase your training volume. A moderate volume (e.g., 3 sets per exercise) is just as effective as high volume (5 sets) for preserving muscle mass, provided you are eating enough protein (approx. 2.8g/kg FFM) and maintaining a moderate caloric deficit. Focus on keeping weights heavy (close to failure) rather than adding extra sets.

Initiating insulin glargine in patients with type 2 diabetes is associated with a higher risk of gastroparesis, intestinal obstruction, and all-cause mortality compared to initiating SGLT2 inhibitors.

If you are considering insulin glargine for type 2 diabetes, know that it is associated with a higher risk of gastroparesis, intestinal obstruction, and death compared to SGLT2 inhibitors. This does not mean insulin is bad, but it highlights the importance of choosing the right medication for your specific health profile. If you are at risk for GI issues, SGLT2 inhibitors might be a safer choice.

Knockout of the microprotein encoded by Adipocyte-smORF-1183 significantly impairs adipocyte differentiation and reduces lipid droplet formation.

This research identifies a specific, previously unknown protein (Adipocyte-smORF-1183) in mouse fat cells that is essential for storing fat. Knocking out this protein reduces fat storage by about half in these cells. While this is a fundamental biological discovery that could lead to future therapies for obesity, it is currently limited to cell culture models and does not yet translate to a direct human treatment or lifestyle intervention.

Higher circulating estrogen levels in women are predictive of increased rates of nausea and vomiting when taking GLP-1 receptor agonists, and estrous cycle phase modulates drug sensitivity in female mice.

Your risk of side effects from GLP-1 drugs may fluctuate with your menstrual cycle, peaking when estrogen is highest. While this paper used mice, human data suggests higher estrogen levels correlate with more nausea. Tracking your cycle might help you and your doctor anticipate and manage side effects.

Daily supplementation with 0.6 g/kg body weight of whey protein does not enhance body composition, core muscle endurance, or joint flexibility adaptations in trained women performing 10 weeks of Pilates training, despite increasing total daily protein intake to ~1.78 g/kg.

If you are a trained woman doing Pilates regularly, adding whey protein supplements on top of your normal diet will not make you lose more fat, gain more muscle, or improve your flexibility compared to just doing the training. Focus on consistent training and adequate whole-food protein intake rather than buying supplements.

Males in the US have consistently higher diabetes incidence and prevalence than females across all age groups, with a significant disparity that becomes more pronounced in older cohorts.

Men in the US are diagnosed with diabetes more often than women, and this gap widens with age. This may be partly due to biological factors and partly due to less frequent healthcare engagement. Men should prioritize regular screening and not delay care due to cultural norms.

The Behavioral Change Technique 'Instruction on how to perform behaviour' is associated with weight GAIN (mean weight change +2.53 kg) rather than loss, suggesting it may be counterproductive in brief, opportunistic primary care advice.

Avoid using 'Instruction on how to perform behaviour' (like handing out leaflets or directing to websites) as a primary strategy in brief weight loss advice. This study found it was associated with weight gain, likely because it is used as a 'simple way to intervene' with patients who are less ready to change. Instead, focus on motivational feedback and follow-up.

Low baseline ribosome-related gene expression and resistance training-induced declines in ribosome-related gene expression are associated with greater skeletal muscle hypertrophy in young men and women.

If you are struggling to build muscle despite consistent resistance training, your baseline cellular machinery (ribosomes) might be a limiting factor, but this is largely genetic or determined by prior activity levels. The key takeaway is that 'more' isn't always 'better' for muscle growth; your body may adapt by becoming more efficient with what it has rather than expanding its capacity. Focus on progressive overload and consistency, as the body's response is individual and not strictly dictated by having the highest possible baseline ribosome levels.

Usual intakes of animal and plant protein are not adversely associated with all-cause, cardiovascular disease, or cancer-related mortality risk in adults.

You do not need to restrict your protein intake, whether from animal or plant sources, to avoid increasing your risk of death from all causes, heart disease, or cancer. The data suggests that typical protein intakes within recommended ranges are safe and not linked to higher mortality.

GLP-1RA treatment induces distinct molecular changes in skeletal muscle proteome (upregulation of mitochondrial proteins) compared to calorie restriction, despite similar weight loss and muscle mass changes.

This finding is primarily mechanistic and suggests GLP-1s may improve muscle metabolic efficiency (mitochondrial function) beyond just weight loss, though this does not currently translate to a specific user action beyond standard treatment.

GLP-1 receptor agonists and MC4R modulators are emerging therapeutic strategies that target hypothalamic pathways to treat metabolic diseases.

Current treatments for obesity and diabetes, such as GLP-1 receptor agonists, work by targeting specific pathways in the hypothalamus. This highlights the importance of central nervous system mechanisms in these conditions and supports the use of these medications as effective treatments.

GLP-1 receptor agonists slow renal disease progression and reduce albuminuria in patients with diabetic kidney disease, although evidence is less robust than for SGLT2 inhibitors.

If you have diabetic kidney disease, GLP-1 receptor agonists may help slow kidney damage and reduce protein in your urine. While there is less data on their kidney benefits compared to SGLT2 inhibitors, they are still considered valuable. Discuss with your doctor if they are appropriate for you, especially if you have cardiovascular risks.

Orforglipron is associated with a dose-dependent increase in gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) and treatment discontinuation rates, particularly at doses of 12 mg and higher.

While effective, orforglipron often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (12 mg and above). These side effects are the main reason people stop taking the medication. Patients should be aware that higher doses provide more weight loss but also carry a higher risk of stopping treatment due to discomfort. Starting at a lower dose and titrating slowly may help manage these side effects.

Discontinuing or interrupting GLP-1 receptor agonist (GLP-1RA) treatment progressively erodes cardiovascular protection, with longer durations of non-use associated with a graded increase in the risk of major adverse cardiovascular events (MACE).

If you have Type 2 Diabetes and take a GLP-1RA (like Ozempic or Wegovy), your heart protection is tied to continuous use. Stopping the medication does not leave you in a 'safe' state; it actively increases your risk of heart attack or stroke, and the longer you stay off the drug, the higher that risk becomes. If you must stop due to side effects or cost, do not just stop abruptly; consult your provider for a strategy to manage the increased cardiovascular risk during the transition.

Standard-of-care weight management in primary care is characterized by extremely low rates of active treatment, with only 12% of eligible patients receiving a weight-prioritized visit and less than 6% receiving any weight-related referral or anti-obesity drug prescription.

If you have a BMI over 25, do not assume your regular doctor is actively treating your weight. In standard practice, most patients like you are not getting referrals or medications. You must explicitly request a 'weight-prioritized visit' or ask for specific interventions (referrals, medications) to break through the system's inertia.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) do not increase the risk of thyroid or pancreatic cancer in humans, despite animal model concerns.

If you are prescribed a GLP-1 agonist like semaglutide or liraglutide, you do not need to worry about an increased risk of thyroid or pancreatic cancer based on current human data. The FDA warning is based on animal studies, and large human trials have not confirmed this risk.

Bariatric surgery reduces the overall incidence and mortality of cancer, with a more pronounced effect in women than men.

Bariatric surgery is a highly effective intervention for reducing the risk of cancer and cancer-related mortality in people with obesity. The benefit is particularly strong for women, likely due to the reduction in hormone-dependent cancers. The risk reduction is directly linked to the amount of weight lost.

Pharmacological inhibition or genetic deletion of the melanocortin-3 receptor (MC3R) enhances the anorectic and weight-loss efficacy of GLP-1 receptor agonists (e.g., liraglutide, semaglutide, tirzepatide) without increasing malaise or peripheral incretin effects.

Current research indicates that blocking the MC3R receptor can make GLP-1 weight loss drugs (like Ozempic or Wegovy) work better, allowing for lower doses to achieve the same weight loss. This happens without increasing the nausea or stomach upset often associated with these drugs. However, effective MC3R-blocking drugs that can cross into the brain are not yet widely available for human use.

MC3R inhibition generalizes to enhance sensitivity to other anorectic hormones, including leptin, peptide YY (PYY3-36), and cholecystokinin (CCK).

Blocking the MC3R receptor doesn't just help GLP-1 drugs; it may also make your body's natural satiety signals (like leptin and gut hormones) work more effectively. This suggests a broader benefit for appetite control beyond just one drug class.

Free leucine supplementation (6g/day split into 3g pre- and post-exercise) does not improve muscle recovery or reduce markers of muscle damage following resistance exercise in untrained young adults consuming adequate dietary protein.

If you are a young, untrained individual eating enough protein (over 1.2g per kg of body weight daily), taking 6 grams of leucine around your workout will not help you recover faster, reduce soreness, or build muscle compared to just eating your normal diet. Save your money on leucine supplements; focus on getting enough total protein and completing your resistance training.

High-sensitivity ELISA assays are required to detect exercise-induced reductions in fasting insulin, whereas standard automated immunoassays (e.g., Immulite 2000) fail to capture these changes despite high correlation with international standards.

If you are tracking insulin response to lifestyle changes (like exercise or diet), ensure your laboratory uses a high-sensitivity ELISA assay. Standard automated immunoassays may report 'normal' or unchanged insulin levels even when significant metabolic improvements have occurred, leading to a false conclusion that the intervention is ineffective.

Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.

Do not rely on current commercial metabolomic tests (like BCAA or detailed lipid panels) to predict whether you will lose weight or improve insulin sensitivity through exercise. These tests may tell you your current risk status, but they cannot tell you how your body will respond to a specific lifestyle change.